市場調查報告書
商品編碼
1384345
免疫球蛋白市場規模(依產品類型(IgG、IgA、IgM)、給藥途徑(靜脈內、皮下)、按應用(原發性免疫缺陷症、繼發性免疫缺陷症)、最終用途(醫院)和預測),2023 - 2032 年Immunoglobulin Market Size by Product Type (IgG, IgA, IgM), By Route of Administration (Intravenous, Subcutaneous), By Application (Primary Immunodeficiency Disease, Secondary Immunodeficiency Disease) By End-use (Hospitals) & Forecast, 2023 - 2032 |
由於免疫缺陷疾病(包括原發性免疫缺陷疾病和繼發性免疫缺陷疾病)發生率不斷上升,免疫球蛋白市場規模預計在2023年和2032年期間CAGR將達7.7%。根據美國國家醫學圖書館 2021 年的報告,全球有超過 600 萬人受到原發性免疫缺陷的影響,其中近 70% 至 90% 未被診斷出來。
免疫球蛋白在治療各種自體免疫疾病和發炎性疾病的廣泛應用正在促進市場成長。正在進行的生物技術研發活動進一步促進了創新免疫球蛋白產品的推出,培育了競爭激烈的市場格局。
整個免疫球蛋白產業根據產品類型、給藥途徑、應用、最終用途和地區進行分類。
到 2032 年,IgA 產品類型細分市場將獲得巨額收入,因為免疫球蛋白 A (IgA) 是免疫系統的關鍵組成部分,可提供針對感染的基本防禦。 IgA可有效預防呼吸道和胃腸道等黏膜組織的感染。隨著研究的進展,基於 IgA 的療法將成為治療各種疾病的有前景的途徑,進一步鞏固該領域的重要性。
預計到2032 年,多灶性運動神經病變(MMN) 領域將出現大幅成長。MMN 是一種以肌肉無力和萎縮為特徵的罕見神經系統疾病,其患病率不斷上升,正在推動對免疫球蛋白治療的需求。隨著臨床試驗和研究工作不斷探索免疫球蛋白在管理 MMN 症狀方面的功效,這個應用領域有望成為一個利潤豐厚的市場途徑。
由於醫療保健支出增加、免疫缺陷疾病盛行率上升以及人口老化,預計亞太地區免疫球蛋白市場從 2023 年到 2032 年將錄得強勁的CAGR。此外,整個地區醫療基礎設施的進步以及人們對免疫球蛋白療法益處的認知不斷提高,正在塑造亞太地區的產業動態。
Immunoglobulin market size is predicted to observe 7.7% CAGR during 2023 and 2032 owing to the escalating incidence of immunodeficiency disorders, including primary immunodeficiency diseases and secondary immunodeficiency diseases. According to a 2021 report by National Library of Medicine, more than 6 million people across the globe are affected by primary immunodeficiencies, of which nearly 70% to 90% are not diagnosed.
The expanding applications of immunoglobulin in treating various autoimmune and inflammatory diseases is bolstering market growth. The ongoing R&D activities in biotechnology are further contributing to the introduction of innovative immunoglobulin products, fostering a competitive market landscape.
The overall immunoglobulin industry is classified based on product type, route of administration, application, end-use, and region.
The IgA product type segment will garner massive revenues by 2032 as immunoglobulin A (IgA) is a key component of the immune system which provides essential defense against infections. IgA is effective in preventing infections in mucosal tissues such as the respiratory and gastrointestinal tracts. As research advances, IgA-based therapies will emerge as a promising avenue in the treatment of various diseases, further solidifying the significance of this segment.
The multifocal motor neuropathy (MMN) segment is anticipated to witness substantial growth through 2032. The rising prevalence of MMN, a rare neurological disorder characterized by muscle weakness and atrophy, is fueling the demand for immunoglobulin therapies. With ongoing clinical trials and research endeavors exploring the efficacy of immunoglobulins in managing MMN symptoms, this application segment is poised to be a lucrative avenue for the market.
Asia Pacific immunoglobulin market is expected to record strong CAGR from 2023 to 2032 owing to the increasing healthcare expenditure, rising prevalence of immunodeficiency disorders, and a growing aging population. Moreover, advancements in the healthcare infrastructure across the region and a surge in awareness regarding the benefits of immunoglobulin therapies are shaping the Asia Pacific industry dynamics.